Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Fatwollit and Rosewood.

Part of Your post:

1. Possibly, TPL might see an advantage in reverse merging Patriot with Intellasys to form a public company dependent on shareholders for funding rather than private sources. I couldn't substantiate that possibility but I wouldn't object to holding shares in Intellasys, knowing that part of its revenue will be based on fees for licensing the MMP and part on its own continuing product development and sales. If the TPL takeover/merger scenario is the one that unfolds, I agree that we'd better watch out if the resulting entity is private.

2.I still can't get my head around Leckrone and Swartz being buddies - they're both too similar. It's been to our advantage for Leckrone to do what he does best and to our disadvantage in Swartz's case. I think Swartz is only interested in making money from struggling companies, as Patriot once was (TPL is not struggling, as far as I know), and in collecting dollars from gullible retail shareholders, as I suspect many of us used to be; I know I was. But not now. What an engrossing story! - it's almost worth being a Patriot shareholder for the entertainment value alone, even if the whole thing ends up going down the tubes!

1. I don't see reverse merging at all. Reason: These guys want to do things in private. They do not want to be accountable to anyone, especially, watchful shareholders and the portfolios and license deals that is in their grand scheme. They can use a million excuses why they think it is better for the MMP to be private, i.e. protect the privacy of J3, ad infinitum. It is impossible to beat lawyers at this game, they are way too smart. They can make an end run while you are concentrating for a run up the middle. They do not want to answer to the SEC in any circumstance or conceivably other governments on a global basis. Only another legal firm is smart enough to play with these guys. TPL wants all this revenue. They have no desire to share their cash cow with anyone. Privacy also allows other patent holders to flock to TPL when they become aware of the TPL story with the MMP. Privacy is something they desire. David Pohl is playing his cards close to the vest. Jim Turley is way over his head. Leckrone and these guys are so smart that the dynasty they are building could reach dramatic proportions.

2. Swartz and Leckrone are not buddies. They could easily be conspiring business partners, along with Pohl and Johnson. Remember the closeness between the Perigrine 3 and Leckrone that has existed for years now. Swartz is focused on struggling companies but this is a golden opportunity to haul in millions at a fixed price per share. He has people on the BOD working for him and he can help TPL gain control of the entire MMP. Remember he has sold at .30's and .40's. He can't touch the huge sums we have in the PTSC coffers but as I said previously, Lambert could probably figure out how much the company is worth and divide it into each share. It may be high and there are still billions out there to get their hands on. The merger may cost them nothing. Swartz walks away with millions in his pocket immediately, to deal with other struggling companies having made hundreds of millions of dollars himself with PTSC deals. Far fetched, probably but I feel not out of the round of possibilities.

Borredo. It is great to see you back here.

Your question on the few million votes available to support merger. Remember, all the votes on the Board and the votes of L&S and remember that if a letter goes out strongly recommending shareholders approve merger as a good deal, many will succumb to the quick money and profit they could realize, especially at say $2 a share. We don't know everyone that is a large shareholder. Many of these could see this as a quick paycheck and they would go on to something else. This is my opinion on this.

Share
New Message
Please login to post a reply